拉米夫定联合替诺福韦与依非韦伦治疗艾滋病的临床效果及对肝功能的影响

Clinical Effect of Lamivudine Combined with Tenofovirdisoproxil and Efavirenz in the Treatment of AIDS and its Effect on Liver Function

目的观察拉米夫定联合替诺福韦与依非韦伦治疗艾滋病的临床效果及对肝功能的影响。方法选取2021年1月-2022年1月在我中心诊治的100例艾滋病患者为研究对象,采用随机数字表法分为对照组(n=50)和观察组(n=50),对照组采用拉米夫定联合依非韦伦治疗,观察组在对照组基础上联合应用替诺福韦,比较两组临床治疗效果、血HIV病毒载量、肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)及总胆红素(T-Bil)]、免疫功能指标(CD4^(+)、CD8^(+))以及不良反应发生情况。结果观察组治疗总有效率为94.00%,高于对照组的80.00%(P<0.05);两组治疗后血HIV病毒载量均低于治疗前,且观察组低于对照组(P<0.05);两组治疗后ALT、AST、T-Bil均升高,但是观察组低于对照组(P<0.05);两组治疗后CD4^(+)、CD8^(+)均高于治疗前,且观察组高于对照组(P<0.05);观察组不良反应发生率为6.00%,与对照组的8.00%比较,差异无统计学意义(P>0.05)。结论拉米夫定联合替诺福韦和依非韦伦治疗艾滋病的临床效果确切,可提高治疗有效率,降低HIV病毒载量,减轻肝功能损伤,促进免疫功能改善,且不会增加不良反应,是一种安全、有效的联合用药治疗方案。

Objective To evaluate the clinical efficacy of lamivudine combined with tenofovirdisoproxil and efavirenz in the treatment of aids and its effect on liver function.Methods A total of 100 AIDS patients diagnosed and treated in our center from January 2021 to January 2022 were selected as the research objects.They were divided into control group(n=50)and observation group(n=50)by random number table method.The control group was treated with lamivudine combined with efavirenz,and the observation group was treated with tenofovirdisoproxil on the basis of the control group.The clinical treatment effect,blood HIV viral load,liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(T-Bil)],immune function indexes(CD4^(+),CD8^(+))and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.00%,which was higher than 80.00%in the control group(P<0.05).The blood HIV viral load of the two groups after treatment was lower than that before treatment,and that of the observation group was lower than that of the control group(P<0.05).After treatment,ALT,AST and T-Bil increased in both groups,but those in the observation group were lower than those in the control group(P<0.05).After treatment,CD4^(+)and CD8^(+)in the two groups were higher than those before treatment,and those in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was 6.00%,which was compared with 8.00%in the control group,the difference was not statistically significant(P>0.05).Conclusion Lamivudine combined with tenofovirdisoproxil and efavirenz has a definite clinical effect in the treatment of AIDS,which can improve the treatment efficiency,reduce HIV viral load,reduce liver function damage,promote immune function improvement,and will not increase clinical adverse reactions.It is a safe and effective combination therapy.